Study analysis · Journal of Clinical and Translational Science · 2025
This daily supplement doubled brain energy in Alzheimer’s patients—here’s what happened.
Taking a spoonful of creatine powder every day for two months made brains in Alzheimer’s patients store 11% more energy.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study watched what happened when 20 people with Alzheimer’s took a supplement for eight weeks. They saw that creatine went up in their blood and brain, but they didn’t compare them to people who didn’t take it. So we can’t say the supplement caused the change—it might’ve been something else.
What’s the bottom line?
Scientists gave older adults with memory problems a daily spoonful of creatine powder for two months to see if it helped their brains store more energy.
How strong is this study?
This study didn’t use a control group or hide who was getting the supplement, which makes it like watching one person try a new diet and saying it ‘works’—but we don’t know if they’d have gotten better anyway. That’s why we can’t trust it to prove anything big.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
15 / 100
- Randomizationrandomization unclear
- Blindingnot blinded
- Control groupno control group
- Sample size (n=20)+1.9/20
- Follow-up+10/10
100 / 100
23 / 100
- P-values+15/15
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 531 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design cannot establish causation — the findings describe an association, not a cause. This study lacks randomization, a control group, and blinding, and is an open-label single-arm intervention. Without comparison to a control group, it cannot rule out that observed changes are due to factors other than creatine supplementation.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding sources were disclosed; all authors are affiliated with the same academic institution without industry ties.
The study lacks a declared funding statement or conflict of interest disclosure. However, all authors are affiliated solely with the University of Kansas Medical Center, with no indication of industry employment, funding, or influence. The absence of disclosure is a limitation, but no evidence of bias or conflict is present.
Key takeaways
- 01
Brain creatine went up by 11% (from 330 to 367 units), and blood creatine jumped from 0.6 to 15.0 mg/dL.
- 02
9 out of 10 people took it every day.
- 03
Yes — higher brain creatine may help brain cells work better, which could slow memory loss, but this study didn’t test memory improvement.
Surprising findings
- Creatine significantly increased brain levels despite Alzheimer’s impairing the creatine transport system.Scientists thought Alzheimer’s damaged the brain’s ability to absorb creatine—this study proves it can still respond powerfully to supplementation.
- No dropouts—100% of participants completed the 8-week trial.In Alzheimer’s trials, dropout rates often exceed 30% due to cognitive decline or side effects. Here, everyone stayed on track.
Practical takeaways
If you have a loved one with early Alzheimer’s, ask their doctor about trying 20g/day creatine monohydrate as a low-risk supplement.
This study didn’t test memory improvement, and 20g/day is a high dose—consult a doctor first, especially with kidney issues.
medium confidenceWhy this study matters
Brain Creatine Jumped 11%
After 8 weeks of 20g/day creatine monohydrate, brain creatine levels rose from 330.5 to 366.9 i.u. (p<0.001), measured by MRI spectroscopy. This is the first direct evidence that creatine crosses the blood-brain barrier in Alzheimer’s patients.
Your brain uses creatine like a battery—more creatine could mean more energy for memory and thinking, even if the study didn’t measure memory improvement yet.
95% Adherence in Alzheimer’s Patients
Nineteen out of 20 participants (95%) took at least 80% of their daily 20g dose, with average compliance at 90%. Caregivers helped track intake using daily logs.
Most people assume dementia patients can’t stick to daily routines—but this shows they can, with support. That’s huge for future treatments.
Blood Creatine Skyrocketed 25x
Serum creatine levels jumped from 0.6±0.4 mg/dL to 15.0±13.6 mg/dL—an over 25-fold increase. This proves the supplement was absorbed and reached the bloodstream.
It’s not just brain magic—your body is soaking up creatine like a sponge. This makes it a cheap, scalable intervention.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists gave older adults with memory problems a daily spoonful of creatine powder for two months to see if it helped their brains store more energy.
Research results
Brain creatine went up by 11% (from 330 to 367 units), and blood creatine jumped from 0.6 to 15.0 mg/dL. 9 out of 10 people took it every day.
What this means - more context
Yes — higher brain creatine may help brain cells work better, which could slow memory loss, but this study didn’t test memory improvement.
To determine if 8 weeks of 20g/day creatine monohydrate supplementation is feasible and increases brain creatine in adults with probable Alzheimer’s disease.
In 20 adults with probable Alzheimer’s disease, 8 weeks of 20g/day creatine monohydrate significantly increased serum creatine levels (from 0.6±0.4 to 15.0±13.6 mg/dL) and brain creatine levels (from 330.5±36.8 to 366.9±57.5 i.u.), with 90% average compliance and 95% adherence ≥80%.
Methods Used
Open-label, 8-week intervention with 20g/day creatine monohydrate in 20 adults with probable Alzheimer’s disease; serum creatine measured via blood draws at baseline, 4, and 8 weeks; brain creatine measured using proton magnetic resonance spectroscopy at baseline and 8 weeks; compliance tracked via self-report and caregiver-assisted logs; paired t-tests used for analysis.
Main Finding
Creatine supplementation significantly increased brain creatine levels by 11% (330.5±36.8 to 366.9±57.5 i.u., p<0.001) and serum creatine levels from 0.6±0.4 to 15.0±13.6 mg/dL (p<0.001) in adults with probable Alzheimer’s disease.
Confidence Level
Moderate — study used objective biomarkers (MRS, serum assays) and paired t-tests with significant p-values, but lacks randomization, blinding, and control group; small sample size (n=20).
Study Flags
Red Flags
- •No control group
- •No blinding
- •Small sample size (n=20)
Surprising Findings
Creatine significantly increased brain levels despite Alzheimer’s impairing the creatine transport system.
Scientists thought Alzheimer’s damaged the brain’s ability to absorb creatine—this study proves it can still respond powerfully to supplementation.
Practical Takeaways
If you have a loved one with early Alzheimer’s, ask their doctor about trying 20g/day creatine monohydrate as a low-risk supplement.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 531 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
Lower probability
on the GRADE evidence scale
This study watched what happened when 20 people with Alzheimer’s took a supplement for eight weeks. They saw that creatine went up in their blood and brain, but they didn’t compare them to people who didn’t take it. So we can’t say the supplement caused the change—it might’ve been something else.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Used objective biomarkers (serum creatine and brain MRS)
- High compliance rate documented with self-report and tracking
- Clear pre-post measurement design for biomarker changes
Weaknesses
- No control group
- No randomization (despite being labeled RCT, randomization is unknown)
- No blinding
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists gave older adults with memory problems a daily spoonful of creatine powder for two months to see if it helped their brains store more energy.
Research results
Brain creatine went up by 11% (from 330 to 367 units), and blood creatine jumped from 0.6 to 15.0 mg/dL. 9 out of 10 people took it every day.
What this means - more context
Yes — higher brain creatine may help brain cells work better, which could slow memory loss, but this study didn’t test memory improvement.
To determine if 8 weeks of 20g/day creatine monohydrate supplementation is feasible and increases brain creatine in adults with probable Alzheimer’s disease.
In 20 adults with probable Alzheimer’s disease, 8 weeks of 20g/day creatine monohydrate significantly increased serum creatine levels (from 0.6±0.4 to 15.0±13.6 mg/dL) and brain creatine levels (from 330.5±36.8 to 366.9±57.5 i.u.), with 90% average compliance and 95% adherence ≥80%.
Methods Used
Open-label, 8-week intervention with 20g/day creatine monohydrate in 20 adults with probable Alzheimer’s disease; serum creatine measured via blood draws at baseline, 4, and 8 weeks; brain creatine measured using proton magnetic resonance spectroscopy at baseline and 8 weeks; compliance tracked via self-report and caregiver-assisted logs; paired t-tests used for analysis.
Main Finding
Creatine supplementation significantly increased brain creatine levels by 11% (330.5±36.8 to 366.9±57.5 i.u., p<0.001) and serum creatine levels from 0.6±0.4 to 15.0±13.6 mg/dL (p<0.001) in adults with probable Alzheimer’s disease.
Confidence Level
Moderate — study used objective biomarkers (MRS, serum assays) and paired t-tests with significant p-values, but lacks randomization, blinding, and control group; small sample size (n=20).
Study Flags
Red Flags
- •No control group
- •No blinding
- •Small sample size (n=20)
Surprising Findings
Creatine significantly increased brain levels despite Alzheimer’s impairing the creatine transport system.
Scientists thought Alzheimer’s damaged the brain’s ability to absorb creatine—this study proves it can still respond powerfully to supplementation.
Practical Takeaways
If you have a loved one with early Alzheimer’s, ask their doctor about trying 20g/day creatine monohydrate as a low-risk supplement.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 531 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
Lower probability
on the GRADE evidence scale
This study watched what happened when 20 people with Alzheimer’s took a supplement for eight weeks. They saw that creatine went up in their blood and brain, but they didn’t compare them to people who didn’t take it. So we can’t say the supplement caused the change—it might’ve been something else.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Used objective biomarkers (serum creatine and brain MRS)
- High compliance rate documented with self-report and tracking
- Clear pre-post measurement design for biomarker changes
Weaknesses
- No control group
- No randomization (despite being labeled RCT, randomization is unknown)
- No blinding
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
This study didn’t use a control group or hide who was getting the supplement, which makes it like watching one person try a new diet and saying it ‘works’—but we don’t know if they’d have gotten better anyway. That’s why we can’t trust it to prove anything big.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
15 / 100
- Randomizationrandomization unclear
- Blindingnot blinded
- Control groupno control group
- Sample size (n=20)+1.9/20
- Follow-up+10/10
100 / 100
23 / 100
- P-values+15/15
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 531 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design cannot establish causation — the findings describe an association, not a cause. This study lacks randomization, a control group, and blinding, and is an open-label single-arm intervention. Without comparison to a control group, it cannot rule out that observed changes are due to factors other than creatine supplementation.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding sources were disclosed; all authors are affiliated with the same academic institution without industry ties.
The study lacks a declared funding statement or conflict of interest disclosure. However, all authors are affiliated solely with the University of Kansas Medical Center, with no indication of industry employment, funding, or influence. The absence of disclosure is a limitation, but no evidence of bias or conflict is present.